EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy

Hannes Lindahl iD, Anna-Carin Norlin, Peter Bergman

Open Forum Infectious Diseases · 01.11.2023 · 10 (11)

DOI: 10.1093/ofid/ofad551 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 14.11.2023. Verfasst von Hannes Lindahl und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis B virus (HBV) core antigen antibodies passively transferred from immunoglobulin products used for replacement or immunomodulation may lead to unnecessary antiviral treatment for patients who are also starting immunosuppressive treatment. We have systematically assessed the contents of 93 commercial immunoglobulin batches and show that there are consistent product-specific differences in the levels of HBV core antigen antibodies and that choice of immunoglobulin product may have an impact on false-positivity rates.

Schlagwörter

Stichwörter der Autor:innen

Common variable immunodeficiencyHBV core antigen antibodiesHepatitis B virusImmunoglobulin replacement therapyPassive immunity

Autor:innen und Institutionen

  • Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Hannes Lindahl

Zitieren

APA

Lindahl, H., Norlin, A. C., & Bergman, P. (2023). Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy. Open Forum Infectious Diseases, 10(11). https://doi.org/10.1093/ofid/ofad551

Vancouver

Lindahl H, Norlin AC, Bergman P. Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy. Open Forum Infectious Diseases. 2023;10(11). doi:10.1093/ofid/ofad551

BibTeX
@article{Lindahl2023,
  author = {Lindahl, Hannes and Norlin, Anna-Carin and Bergman, Peter},
  title = {Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy},
  journal = {Open Forum Infectious Diseases},
  year = {2023},
  volume = {10},
  number = {11},
  doi = {10.1093/ofid/ofad551}
}
Kostenlos starten →